Meeting
2016 ASCO Annual Meeting
Porocarcinoma expression of high EGFR levels and sensitivity to EGFR or/and MEK inhibition.
Authors
Friedegund Elke Meier
Universitatsklinikum Carl Gustav Carus, Dresden, Germany
Friedegund Elke Meier , Mildred Sergon , Marlene Garzarolli , Arno Ruetten , Sophia Blum , Michael Laniado , Selma Ugurel , Jan Maschke , Stefan Beissert , Dagmar Kulms , Dana Westphal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 34, 2016 (suppl; abstr 9545)
DOI
10.1200/JCO.2016.34.15_suppl.9545
Abstract #
9545
Poster Bd #
150
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
MAPK pathway alterations as a targetable vulnerability in bladder cancer.
First Author: Vincent D'Andrea
Poster
2023 ASCO Annual Meeting
Development of bifunctional CRBN-SOS1 degraders for treatment of mutant KRAS cancers.
First Author: Kyle Begovich
Poster
2022 ASCO Annual Meeting
Phase 2 study of anti-EGFR rechallenge therapy with panitumumab with or without trametinib in advanced colorectal cancer.
First Author: Christine Megerdichian Parseghian
Poster
2020 ASCO Virtual Scientific Program
A phase II study of ERK inhibition by ulixertinib (BVD-523) in metastatic uveal melanoma.
First Author: Elizabeth Iannotti Buchbinder